Journals / Türk Oftalmoloji Dergisi / 2009 / Cilt: 39 - Sayı: 1

Intraocular pressure elevation after intravitreal triamcinolone acetonide injection and predictive factors

İntravitreal triamsinolon asetonid uygulaması sonrası göziçi basınç artışı ve etiyolojide etkili faktörler

Pages
37–42
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean age of the patients with high IOP after the injection was significantly lower than the mean age of the study group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To analyze the incidence of intraocular pressure (IOP) elevation following intravitreal triamcinolone acetonide (IVTA) injection and predictive factors for IOP elevation.
📊
Key Findings & Data:METHODS: Charts of 179 patients of 217 eyes who underwent IVTA injection between January 2005- May 2007 were retrospectively reviewed.
💡
Conclusion & Impact:The mean age of the patients with high IOP after the injection was significantly lower than the mean age of the study group (p
🔬Design:Review & Systematic Survey
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

PURPOSE: To analyze the incidence of intraocular pressure (IOP) elevation following intravitreal triamcinolone acetonide (IVTA) injection and predictive factors for IOP elevation. METHODS: Charts of 179 patients of 217 eyes who underwent IVTA injection between January 2005- May 2007 were retrospectively reviewed. All cases underwent full ophthalmological examination before IVTA injection. Indications of IVTA injection, IVTA doses, injection times, systemic disease, history of glaucoma were noted. RESULTS: Mean follow-up was 8.85 ± 7.125 months (1-41 months). Mean age of the patients was 62,7 ± 12,7 years (21-88 years). 173 (80 %) eyes received 4 mg /0.1 ml of TA, 44 (20 %) eyes received 2 mg /0.1 ml of TA. The mean baseline of IOP was 14.54 ± 1.86 mmHg (10-21 mmHg). Fifty -three eyes (%24.4) showed IOP elevation of five mmHg or higher after the IVTA injection. Fourty-eight out of 53 eyes (%90.5) received 4 mg /0.1 ml of single dose of TA. IOP was higher than 15 mmHg before the IVTA injection in 36 (68 %) out of 53 eyes. Twenty-seven (51 %) of these eyes received topical medication. Viscocanolostomy was performed in two patients. The mean age of the patients with high IOP after the injection was significantly lower than the mean age of the study group (p

Özet

AMAÇ: İntravitreal triamsinolon asetonid (İVTA) uygulaması sonrası göziçi basınç (GİB) artışı ve etyolojide etkili faktörleri araştırmak. GEREÇ-YÖNTEM: Ocak 2005- Mayıs 2007 tarihleri arasında İVTA uygulanan 179 hastanın 217 gözü retrospektif olarak incelendi. Tüm hastalara enjeksiyon öncesinde tam bir oftalmolojik muayene yapıldı. Yapılan enjeksiyon sayısı, dozu, İVTA yapılma endikasyonları, sistemik hastalık, glokom öyküsü kaydedildi. BULGULAR: Ortalama takip süresi 8.85 ± 7.125 ay (1-41ay) idi. Ortalama yaş 62.7 ± 12.7 (21-88 yaş) idi. Gözlerin 173’üne (%80) 4 mg/0.1 ml, 44’üne (%20) 2 mg /0.05 ml İVTA yapıldı. Enjeksiyon öncesi ortalama GİB’ı 14,54 ± 1,86 mmHg (10-21mmHg) idi. İVTA enjeksiyonu sonrasında 53 gözde (%24.4) GİB’ında beş mmHg ve üzerinde artış saptandı. Bunların 48’ ine (%90.5) 4 mg/0.1ml dozunda, tek İVTA enjeksiyonu yapılmıştı. Beş mmHg ve üzerinde GİB artışı gözlenen 53 gözün (42 olgu) 36’sında (%68) enjeksiyon öncesi GİB’ı 15 mmHg üzerindeydi, 27’sine (%51) ilaç başlandı, iki hastaya viskokanolostomi yapıldı. GİB artışı saptanan hastaların yaş ortalaması, toplam hasta yaş ortalamasına göre anlamlı düzeyde düşüktü (p

🔖

Cite This Article

KAYA, M., ERGİN, M., KOÇ, T., ARİKAN, G., KAYNAK, S., GÜNENÇ, Ü., KOÇAK, N. (2022). Intraocular pressure elevation after intravitreal triamcinolone acetonide injection and predictive factors. Türk Oftalmoloji Dergisi, Cilt: 39 - Sayı: 1, 37–42. https://ajindex.com/articles/638537

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Oph-thalmol Soc 1979
  2. McCuen BW, Besler M, Tano Y, Chandler D, Machemer R
  3. The lack of toxicity of intravitreally administered tri-amcinolone acetonide. Am J Ophthalmol 1981
  4. Jonas JB, Hayler JK, Sofker AP, Jonas S: Intravitreal injection of crystalline cortisone as adjunctiv treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001
  5. Edelman J, Lutz D, Castro MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-aqueous barrier breakdown. Exp Eye Research 2005
  6. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoa-gulation. Arch Ophthalmol 1992
  7. Jonas JB, Hayler JK, Sofker AP, Jonas S: Regression of neovascular iris Vessels by intravitreal injection of crystalline cortisone. J Glaucoma. 2001
  8. Martidis A, Duker JS, Greenberg PB, et al: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002
  9. Jonas JB, Kreissig I, Degenring R: Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005
  10. Enaida H, Hata Y, Ueno A, Nakamura T, Hisatomi T, Miyazaki M, Fujisawa K, Sakamoto T, Ishibashi T: Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina 2003
  11. Sobrin L, D'Amico DJ: Controversies in intravitreal triamcinolone acetonide use. Int Ophthalmol Clin 2005
  12. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Preliminary results of a prospective controlled trial. Oph-talmology 2004
  13. Sutter FKP, Simpson JM, Gillies MC: Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophthalmology 2004
  14. Karaçorlu M, Özdemir H, Karaçorlu S, Alacali N, Mudun B, Bürümcek E: intravitreal triamcinolone as a primary therapy in diabetic macular edema. Eye 2005
  15. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S: Intravitreal triamcinolone for treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomogr